- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00331370
Hypertension Related Damage to the Microcirculation in South Asian: Emergence, Predictive Power and Reversibility
Hypertension Related Damage to the Microcirculation in South Asian: Emergence,Predictive Power and Reversibility
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background
The role of the microcirculation is increasingly being recognized in the etiopathogenesis of cardiovascular disease. Delays in this recognition are in part due to the difficulty of studying the microcirculation non-invasively, in large numbers of individuals. Retinal vessels provide an easily accessible "window" to the microcirculation. Abnormalities of the retinal vasculature have been shown to be associated with cardiovascular risk factors and all cause mortality. Non-invasive assessment of the retinal circulation presents a valuable opportunity to study the structure and function of the microvasculature
Aims of the project
To compare geometry of retinal microvasculature of 1) hypertensive vs normotensive adults, 2) children aged 10 to 14 years of hypertensive parent (test group) versus normotensive parent (control group), and, 3) to assess the impact of blood pressure lowering on these changes over 2 years.
Primary outcome would be abnormal retinal geometry defined as the composite outcome of a) abnormal arteriolar length: diameter ratios (a measure of relative arteriolar narrowing), b) narrowed branching angles (an indicator of arteriolar rarefaction), or c) disturbed junction exponents (a marker of endothelial dysfunction.
Significance of the study
If successful, this work could be extended to address future questions, including the predictive value of these abnormalities for development of diabetes and hypertension as well as CVD; to explore further the role of microvascular disturbances in disease etiology, and to assess the impact of drug therapy on these abnormalities and their relationship to outcomes in the South Asian population
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Sindh
-
Karachi, Sindh, Pakistan, 74800
- Aga Khan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All subjects aged 9 years or over residing in randomly selected communities
Exclusion Criteria:
Pregnancy
Those who have severe co-morbid conditions
Patients with known history of glaucoma will be excluded from our study because instillation of mydriatic drops was thought to be hazardous for them.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Primary outcome would be abnormal retinal geometry defined as the composite outcome of a) abnormal arteriolar length: diameter, b) narrowed branching angles, or c) disturbed junction exponents.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tazeen H Jafar, MD, MPH, Aga Khan University
- Study Chair: Nish Chaturvedi, MD, MFPHM, Imperial College London
- Study Chair: Alun Hughes, MD, Phd, Imperial College London
- Study Chair: Juanita Hatcher, Phd, MSc, Aga Khan University
- Study Chair: Simon Thom, MD, FRCP, Imperial College London
- Study Chair: Khabir Ahmad, MD, MSc, Aga Khan University
- Study Chair: Muhammad Saleem Khan, MSc Epi&Bio, Aga Khan University
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DHCPP00493
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.